et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68: 293–8. , ,
Advances in the management of epithelial ovarian cancer. J Reprod Med 2001; 46: 621–9; discussion 9–30. , .
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231–5. , , .
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396–410. , .
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006; 7: 192–8. , .
et al. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica 2006; 91: 1105–8. , ,
et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep 2008; 20: 379–84. , ,
Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide. Exp Toxicol Pathol 2008; 60: 481–8. , , , , .
et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97: 675–81. , ,
et al. Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol 2006; 23: 231–43. , ,
Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol Oncol 2005; 99: 726–9. , , , , .
Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 2006; 103: 199–206. , .
et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003; 101: 4576–82. , ,
Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin 2003; 24: 646–50. , , .
et al. Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 2004; 12: 573–80. , ,
Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep 2008; 35: 421–9. , , , , .
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55. , .
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–81. .
CompuSyn Software for Drug Combinations and for General Dose-Effect Analysis, and User’s Guide. Paramus, NJ: ComboSyn, 2007. , .
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 2008; 18: 147–51. , , .
et al. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. Int J Gynecol Cancer 2005; 15: 872–7. , ,
et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 2004; 22: 63–71. , ,
et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 5328–35. , ,
et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469–73. , ,
Treatment options in the management of ovarian cancer. Expert Opin Pharmacother 2005; 6: 743–54. , , , , .
et al. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol 2000; 23: 569–74. , ,
Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2002; 12: 710–4. , , , , .
et al. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol 2006; 57: 491–9. , ,
Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008; 49: 2059–80. .